Fexuprazan vs Esomeprazole Efficacy and Safety Meta-Analysis for GERD

Omar Abureesh's systematic review and meta-analysis compares the new potassium-competitive acid blocker fexuprazan to esomeprazole for treating gastroesophageal reflux disease. The analysis includes data from five studies covering 965 patients over a mean treatment period of 9.6 weeks. It was uploaded to figshare on May 7, 2026, under a CC-BY-4.0 license.

Use Cases

• Comparing treatment efficacy between drug classes based on GERD symptom scores and patient-reported improvement rates.
• Assessing drug safety profiles based on reported treatment-emergent adverse events and adverse drug reactions.
• Conducting secondary meta-analyses on P-CAB drugs versus proton-pump inhibitors.
• Informing clinical trial design for future studies on fexuprazan.

Strengths

• Analysis is based on five distinct studies aggregating data from 965 patients.
• Includes specific statistical results such as standardized mean differences and risk ratios with confidence intervals.
• Follows a documented systematic review methodology including risk of bias assessment.

Limitations

• The primary data file is a 15.9 KB DOCX document; the underlying raw dataset columns and structure are unknown.
• Row count for any underlying tabular data is unknown, limiting suitability assessment for direct ML use.
• The description focuses on aggregated results, not individual patient-level data.

Provenance

Source

Omar Abureesh via figshare.

Collection Method

Systematic review and meta-analysis of published clinical studies.

Freshness

Last updated 2026-05-07 05:42:16